
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.
Ginkgo Bioworks reported quarterly sales of $148.00 million which beat the analyst consensus estimate of $94.81 million by 56%. This is a 363% increase over sales of $32.00 million in the same period last year.